arXiv Science⌕ Search
Home/Archive/arXiv

arXiv · 2609.13322

SenSASP: A Unified, Multi-Layer Database of Senescence and SASP Genes

Hao Xuan·Yu Huang·Jiang Bian
View original source ↗Read source document ↗Export metadata ↓

Abstract

Research on cellular senescence and the senescence-associated secretory phenotype (SASP) draws on independently curated gene resources that differ in scope, identifiers, and update cycles, making cross-resource integration error-prone. We unified four widely used resources, CellAge, GenAge, the SenMayo signature, and the Reactome Cellular Senescence pathway, onto a single canonical identifier (the Ensembl gene ID) and enriched every gene with three annotation layers absent from all four inputs: cross-species conservation, tissue and cell-type expression, and high-confidence protein-protein interactions. Unification collapsed 1,460 summed source entries into 1,250 unique genes (210 redundant entries removed, 14.4%) while preserving full source provenance: 173 genes are corroborated by two or more resources and two (IL6, JUN) by all four. The three annotation layers reach 95.8%, 97.9%, and 93.0% of genes, with 89.4% annotated across all three. A 500-gene random sample of identifier mappings was validated against HGNC and Ensembl (98.0% exact match). The result, SenSASP, is a single, machine-readable, provenance-tracked database of harmonized identifiers and net-new functional context, illustrated here with a gene-prioritization score and a tissue-expression atlas. SenSASP is freely available at https://xuan13hao.github.io/sensasp/

Explore related subjects

q-bio.OT

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hao Xuan, Yu Huang, Jiang Bian. 2026-09-10. SenSASP: A Unified, Multi-Layer Database of Senescence and SASP Genes. https://arxiv.org/abs/2609.13322

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

EPI-KAN: A Method For Estimating and Forecasting Time-Dependent COVID-19 Parameters

We introduce EPI-KAN, a novel method for estimating COVID-19 time-varying parameters. EPI-KAN uses historical epidemiological data, Physics-Informed Neural Network (PINN), and the novel Kolmogorov-Arnold Network (KAN). The method harnesses the novel Kolmogorov-Arnold Network (KAN), which is a type of artificial neural network. For the KAN in this paper, we learn activation functions that are represented using Fourier series, hence we abbreviate as KAN-F. In this study, we estimate parameters in the context of an SIRD compartmental differential equations. The time-dependent parameters are the transmission rate $β(t)$, recovery rate $γ(t)$, and mortality rate $μ(t)$. We define three KAN-F functions $\widehatβ$, $\widehatγ$, $\widehatμ$ that model the true parameters $β(t)$, $γ(t)$, $μ(t)$, respectively. We test two model architectures for the KAN-F: the first has 8 input variables consisting of $S$, $I$, $R$, $D$, and their numerical gradients at any time $t$, while the second has 4 input variables excluding the numerical gradients. The objective loss function that has to be minimized is subject to Physics-Informed Neural Network (PINN). Using historical data of COVID-19 from three South-East Asian countries: Indonesia, Singapore, and Malaysia, we are able to estimate $β(t)$, $γ(t)$, and $μ(t)$ on each country with decent accuracy and efficiency. The time period of choice coincides with the period where SARS-CoV-2 Delta variant (B.1.617.2) was dominant. In addition to estimating the rates during the training period, we also predict transmission rates over 30 days during forecast period. We found that the output of KAN-F over the forecast period can give good predictions if we scale the output by a factor of 17\% for Indonesia and 30\% for Singapore and Malaysia.

q-bio.OT↗
arXiv2026

Making Models That Matter: How to Build Trustworthy and Useful Systems Biology Models

Computational models supporting mechanistic understanding of (complex) biological systems, systems behaviour prediction, and experimental design are becoming more and more embedded in research on complex biological systems. Reuse and refinement of models, rather than continuous reinvention, is becoming increasingly important as models' demands on computational infrastructure increase. However published models - despite the variety of efforts taken so far - are frequently difficult to reproduce or reuse, substantially limiting their scientific value. Here we address the requirements for model reusability in the light of the field-specific CURE framework (Credible, Understandable, Reproducible, Extensible) and the more general FAIR principles (Findable, Accessible, Interoperable, Reusable). Considering published guidance we identify broad agreement on requirements for findability, accessibility, and interoperability, but continued lack of clarity and consensus around reusability. Focusing on the scientific quality and usability of computational models we discuss six key practices underpinning model sharing and re-use. Mapping the FAIR and CURE principles onto the model lifecycle we propose ten recommendations for building and sharing systems biology models that are both FAIR- and CURE-compliant.

q-bio.OT↗
arXiv2026

MarkerScout: A Disease-Agnostic Machine Learning Framework for Biomarker Prediction from Multi-Scale Mechanistic Models

We demonstrate the framework on three infectious diseases derived from a companion mechanistic immune-simulation platform: SARS-CoV-2, Influenza A Virus, and Plasmodium falciparum. Each disease was evaluated across hospitalization and intensive care unit cohorts, yielding six cohorts in total. Best-pipeline cross-validated macro F1 ranged from 0.82 for IAV-HOSP to 0.99 for COV-ICU, and the framework produced tiered, direction-aware biomarker lists for each disease and phase. Interleukin-18 (IL-18) reached the strongest tier in both SARS-CoV-2 phases with consistent direction. When benchmarked against three separate, independently collected clinical ICU datasets, MarkerScout's top-ranked features outperformed 94.4% of randomly selected feature sets of equivalent size for SARS-CoV-2, with a weaker but directionally consistent advantage for Influenza A Virus (66.7%) and Plasmodium falciparum (60.7%).

q-bio.OT↗